Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Brief Summary: This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to standard platinum-based chemotherapy concurrently in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.


Options:
A: Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD 40mg/m2 ivgtt q4w | Arm Label: PLD + Apatinib; Type: EXPERIMENTAL; Interventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Assigned to Arm(s): PLD + Apatinib | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w; Assigned to Arm(s): PLD
B: Arm Label: Phase 3 -Active Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: AL3818, Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin (PLD), Drug: Topotecan | Arm Label: Phase 3-Control Treatment Arm; Type: OTHER; Interventions: Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin (PLD), Drug: Topotecan | Arm Label: Phase 1b: AL3818 plus carboplatin and paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: AL3818 | Arm Label: Phase 2a: AL3818 plus carboplatin and paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: AL3818 | Intervention Type: DRUG; Name: AL3818; Assigned to Arm(s): Phase 3 -Active Treatment Arm | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Phase 3 -Active Treatment Arm, Phase 3-Control Treatment Arm | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin (PLD); Assigned to Arm(s): Phase 3 -Active Treatment Arm, Phase 3-Control Treatment Arm | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Phase 3 -Active Treatment Arm, Phase 3-Control Treatment Arm | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Phase 3 -Active Treatment Arm, Phase 3-Control Treatment Arm | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Phase 1b: AL3818 plus carboplatin and paclitaxel, Phase 2a: AL3818 plus carboplatin and paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Phase 1b: AL3818 plus carboplatin and paclitaxel, Phase 2a: AL3818 plus carboplatin and paclitaxel | Intervention Type: DRUG; Name: AL3818; Assigned to Arm(s): Phase 1b: AL3818 plus carboplatin and paclitaxel, Phase 2a: AL3818 plus carboplatin and paclitaxel
C: Arm Label: Pazopanib/Paclitaxel association; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Paclitaxel | Arm Label: Paclitaxel alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib/Paclitaxel association | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel alone, Pazopanib/Paclitaxel association
D: Arm Label: Bevacizumab combined with Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Bevacizumab combined with chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Fluzoparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: chemotherapy; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: Fluzoparib; Assigned to Arm(s): Fluzoparib

Answer: B